

## References

I-123

1. Hole S, Pedersen A, Hansen S, Lundqvist J, Yde C, Lykkesfeldt A. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. *Int J Oncol*. 2015;46(4):1481-1490.
2. Ellis M, Llombart-Cussac A, Robertson J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. *J Clin Oncol*. 2015;33(32):3781-3787.
3. Cristofnili M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17(4):425-439.
4. Musolino A, Campone M, Neven P et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2— breast cancer that had progressed during or after prior endocrine therapy. *Breast Cancer Res*. 2017;19(1):18.
5. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*. 2017;35(25):2875-2887.
6. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im S, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. *Oncologist*. 2017;22(9):1028-1038.
7. Xu L, Yan N, Li Z, et al. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis. *Onco Targets Ther*. 2018;11:8389-8398.
8. Quenel-Tueux N, Debled M, Rudewicz J, et al. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. *Br J Cancer*. 2015;113(4):585-594.
9. Zhang T, Feng F, Zhao W, et al. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: A network meta-analysis. *Cancer Manag Res*. 2018;10:5869-5880.
10. Fulvestrant In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 10, 2017.
11. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Fulvestrant.
12. Micromedex DrugDex Compendium®. 2024.Fulvestrant.
13. National Comprehensive Cancer Network (NCCN). Fulvestrant. NCCN Drugs and Biologics Compendium®. 2024.
14. Faslodex® (Fulvestrant) injection, for intramuscular use [package insert]. AstraZeneca Pharmaceuticals LP. Wilmington, DE. Revised 08/2020.